Categories: Science and Technology

DCGI gives final approval for Covid-19 vaccines of SII, Bharat Biotech

The Drugs Controller General of India (DCGI) has formally announced the final approval for Oxford-AstraZeneca “Covishield” and Bharat Biotech “Covaxin” vaccines against the coronavirus disease (Covid-19) for emergency use. CDSCO (Central Drugs Standard Control Organisation) accepts the subject expert committee reform rations on Serum and Bharat Biotech Covid vaccines.

About Covishield:

The subject expert committee (SEC) under CDSCO had recommended Oxford-AstraZeneca’s vaccine, which is being manufactured by the Serum Institute of India (SII) as Covishield, for emergency use and Covaxin for restricted use.

About Covaxin:

Covaxin is the indigenous vaccine being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

Important takeaways for all competitive exams:

Serum Institute of India CEO: Adar Poonawalla.
Serum Institute of IndiaFounder: Cyrus S. Poonawalla.
Serum Institute of IndiaFounded: 1966.
Serum Institute of India Headquarters location: Pune.

Sumit Arora

As a team lead and current affairs writer at Adda247, I am responsible for researching and producing engaging, informative content designed to assist candidates in preparing for national and state-level competitive government exams. I specialize in crafting insightful articles that keep aspirants updated on the latest trends and developments in current affairs. With a strong emphasis on educational excellence, my goal is to equip readers with the knowledge and confidence needed to excel in their exams. Through well-researched and thoughtfully written content, I strive to guide and support candidates on their journey to success.